Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-188E + Pembrolizumab in Advanced HPV-Positive Cervical Cancer
NCT03444376Phase 2Completed
- Sponsor
- Genexine
- Start
- Jun 2018
- Primary completion
- Apr 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of tirvalimogene teraplasmid in Cervical Cancer (CC), sponsored by Genexine. Started Jun 2018; status: completed.
02
Drugs
tirvalimogene teraplasmid
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03444376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444376.